

Advances in Immunotherapy for Genitourinary Malignancies

Guest Editor:

Prof. Amirali Salmasi
Department of Urology,
University of California, San
Diego Health, San Diego, CA
92103, USA

Deadline for manuscript
submissions:

closed (15 August 2023)


Message from the Guest Editor

Dear Colleagues,

Over the last few years, immunotherapy has become an increasingly attractive treatment modality in many solid tumors, including genitourinary malignancies. Novel immunotherapy strategies offer a promising approach to improve the overall survival and quality of life outcomes for cancer patients. The discovery of checkpoint inhibitors has significantly changed the field of cancer immunotherapy. However, more studies will be required to understand how to manipulate the immune system to improve anti-tumor activity by combining checkpoint inhibitors with other immune co-stimulatory therapies and/or conventional cancer therapies. In this Special Issue, experts in the field will review and present advances in understanding and modulating the immune microenvironment of genitourinary malignancies.

Prof. Amirali Salmasi
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)